Our research in Immunology

Intended for healthcare professionals, scientific audiences and media.  

Pursuing pathbreaking science in Immunology

Giovanni Caforio on Bristol Myers Squibb's leadership in Immunology

Hear from our Board Chair and CEO, Giovanni Caforio, M.D., about our commitment to elevating patient care to new standards to deliver what matters most – the promise of living a better life.

 

At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and neurology. While there has been progress with medicines for immune-mediated diseases, people living with these conditions may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their daily life.

Our goal is to restore some of what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.

Immunology focus areas

Our scientific innovation

Bristol Myers Squibb is focused on delivering scientific innovation with the empathy and urgency needed to advance care for people living with immune-mediated diseases. 

As we continuously build and expand our portfolio, our teams work to identify mechanisms that may reset and promote balance in the immune system, with the goal of achieving long-term remission and, ultimately, curative therapies. 

Pioneering paths forward in immunology

Hear from Jonathan Sadeh, MD, MSc, senior vice president of Immunology and Fibrosis Development at Bristol Myers Squibb, about how the company aims to build a robust immunology portfolio with pathbreaking science that addresses the unmet needs of people living with immune-mediated diseases.


Exploring pathways in immune-mediated diseases to advance patient care

Alyssa Johnsen, MD, PhD, vice president & head of clinical development, Immunology & Fibrosis at Bristol Myers Squibb, shares her perspective on the great strides that have been made in the science of modulating the body's immune response to treat disease.

Meet our Immunology researchers

Elizabeth (Liz) Colston, M.D., Ph.D. >

Clinical Development Lead, Dermatology, Central New Jersey

Richard Hargreaves, Ph.D. >

Senior Vice President, Neuroscience Thematic Research Center, Central New Jersey

Robert Plenge, M.D., Ph.D. >

Senior Vice President and Head, Immunology, Cardiovascular and Fibrosis Thematic Research Center; Head, Translational Medicine, Cambridge, Massachusetts

Jonathan Sadeh, MD, MSc  >

Senior Vice President, Head of Immunology and Fibrosis Development, Global Drug Development, Central New Jersey

Alyssa Johnsen, MD, PhD >

Vice President and Head of Clinical Development, Immunology and Fibrosis

Our presence at upcoming conferences




Join us as we transform patients’ lives through science

Every day, each of us works to improve outcomes for patients fighting serious immune-mediated diseases. We're creative thinkers motivated by the practical application of our work, and innovators unafraid to step into uncharted territory. Together, we're building a better future for each other and the patients who need us most. 

Rheumatology

Over 20 years ago, Bristol Myers Squibb pioneered the science of modulating the body’s immune response to treat disease, beginning with the company’s research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and ankylosing spondylitis. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.

The American College of Rheumatology (ACR) Convergence 2022 meeting represents an important opportunity to review and share the latest research for people living with immune-mediated rheumatic diseases. We are looking forward to sharing 17 company-sponsored presentations, including clinical and health economics and outcomes research data across systemic lupus erythematosus, psoriatic arthritis and rheumatoid arthritis that further showcase the strength and depth of our robust portfolio. Together, our data continue to demonstrate our commitment to pursuing innovative science to address unmet needs for the rheumatology community.

BMS' commitment to precision medicine for patients living with immune-mediated diseases >

Hear Kellie Calderon, MD, medical director at Bristol Myers Squibb, explain the importance of collaboration and precision medicines in the study of immune-mediated disease.

Lupus: Treatments, Research and Bristol Myers Squibb's Dedication to Patients  - A Q&A With Subhashis Banerjee >

Subhashish Banerjee, MD, vice president & disease area head, Rheumatology and Dermatology at Bristol Myers Squibb, shares how the company is leveraging a pathways-based approach to advance research and ultimately elevate care for patients in need of new treatment options in systemic lupus erythematosus (SLE), also known as lupus.

Our precision-focused approach in RA and beyond: a Q&A with Dr. Sean E. Connolly >

Learn more about our work in rheumatology and what people impacted by immune-mediated diseases need to know.

Pursuing innovative approaches to advance research for psoriatic disease >

Shalabh Singhal, vice president, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.

Rheumatoid arthritis >

Learn more about RA, its symptoms and its potential impact on patients. 

Psoriatic arthritis >

Learn more about psoriatic arthritis, its symptoms and its potential impact on patients. 

Juvenile idiopathic arthritis >

Learn more about juvenile idiopathic arthritis, its symptoms and its potential impact on patients.

Systemic lupus erythematosus >

Learn more about systemic lupus erythematosus, its symptoms and its potential impact on patients. 

Ankylosing spondylitis >

Learn more about ankylosing spondylitis, its symptoms and its potential impact on patients. 

Biomarkers in rheumatoid arthritis >

Learn how biomarkers in RA can provide clues to diagnosis and insights into overall prognosis and have the potential to inform treatment strategies.

TYK2 pathway >

Learn about the scientific mechanism behind the TYK2 pathway and its role in immune-mediated diseases.

Gastroenterology

Bristol Myers Squibb is pursuing innovative research to potentially change the course of gastrointestinal immune-mediated diseases, including inflammatory bowel disease (IBD) (which includes ulcerative colitis and Crohn's disease) and eosinophilic esophagitis (EoE). Our scientific innovations have the potential to provide relief and remission to people living with these conditions.

The American College of Gastroenterology (ACG) 2022 annual meeting, taking place from October 21-26, is an important opportunity to showcase the latest advances in gastrointestinal research. Bristol Myers Squibb will be presenting 12 company-sponsored abstracts expanding on clinical data that demonstrate our commitment to addressing unmet needs for patients living with gastrointestinal immune-mediated diseases.

IBD: research, partnerships and Bristol Myers Squibb's dedication to patients >

Learn about Bristol Myers Squibb’s commitment to advancing IBD research for patients in need from Mark Osterman, M.D., vice president, disease area head, Gastroenterology.

Understanding the needs of people living with IBD >

Learn how Bristol Myers Squibb is committed to ongoing research in IBD.

Break the silence: shining a light on IBD >

Read a Q&A with leaders of European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) regarding World IBD Day, and learn about the importance of advocating for patients suffering from various IBDs.

Winter's story: living with ulcerative colitis >

Learn about Winter's journey of living with ulcerative colitis for more than 20 years.

Ulcerative colitis >

Learn more about ulcerative colitis, its symptoms and effects on patients. 

Crohn's disease >

Learn more about Crohn’s disease, a gastrointestinal immune-mediated disease that affects patients worldwide.

Eosinophilic esophagitis >

Learn more about EoE, a gastrointestinal immune-mediated disease that affects patients worldwide.

S1P signaling >

Learn about the role of sphingosine-1-phosphate (S1P) signaling and its relationship to gut inflammation.

TYK2 pathway >

Learn about the scientific mechanism behind the tyrosine kinase 2 (TYK2) pathway and its role in immune-mediated diseases.

The IBD Global Assessment of Patient & Physician Unmet Needs Survey (GAPPS) is a resource for U.S. healthcare professionals to learn more about the impact of the evolving IBD treatment landscape on patients with ulcerative colitis and Crohn’s disease.

Dermatology

Through Bristol Myers Squibb’s pioneering exploration of immune pathways implicated in dermatologic conditions, our discovery team’s research is leading to the potential for safe, effective, category-defining new therapies that may address the pressing treatment gaps that continue to exist for people living with these conditions. With a highly focused pipeline, we are pursuing novel treatments for psoriasis and atopic dermatitis and exploring a broad range of serious dermatologic conditions in our early research.

The European Academy of Dermatology and Venereology (EADV) Congress serves as an important opportunity to engage in scientific exchange with the dermatology research and medical community, and Bristol Myers Squibb looks forward to presenting 26 abstracts at this year’s meeting. This research reinforces the company’s unwavering commitment to pursuing pathbreaking science, with the goal of elevating care for people living with serious immune-mediated diseases, like psoriasis.  

Patient experience of living with psoriasis >

Learn about Royce Thomas' experience of living with psoriasis, as he speaks with Frida Dunger Johnsson, executive director of IFPA, and the importance of supporting the global community of individuals impacted by psoriatic disease.

Pioneering new paths forward in psoriasis >

Renata M. Kisa, M.D., discusses the company’s focus in dermatology research, how unmet needs drive the pipeline forward and what motivates Bristol Myers Squibb to make a difference for patients.

Becoming united: raising awareness globally on World Psoriasis Day >

Frida Dunger Johnsson, executive director of IFPA, and Janina Kostiukaite, project developer, sat down with Bristol Myers Squibb to discuss the importance of uniting to support those with psoriatic diseases. 

Understanding key psoriasis outcome measures  >

Bristol Myers Squibb is committed to educating patients and healthcare providers about psoriasis so that they can work together to determine a disease management plan.

Psoriasis >

Learn more about psoriasis, its symptoms and potential impact on patients.

Atopic dermatitis >

Learn more about atopic dermatitis, its symptoms and its potential impact on patients.

Psoriatic arthritis >

Learn more about psoriatic arthritis, its symptoms and its potential impact on patients.

TYK2 pathway >

Learn about the scientific mechanism behind the tyrosine kinase 2 (TYK2) pathway and its role in immune-mediated diseases.

Learn about the TYK2 pathway and its role in immune-mediated diseases like psoriasis.

Psoriasis treatment types >

Learning more about different types of treatment options can help people work with their healthcare providers on the approach best suited to their needs.

Neurology

At Bristol Myers Squibb, we are focused on delivering solutions that may help preserve physical and cognitive function in people living with neurological conditions like multiple sclerosis (MS). Building on our experience, we are pursuing pathbreaking science to improve care for those impacted by the disease. By helping restore some of what MS has taken away, we aim to empower people living with MS and their loved ones to take back control of their lives. 

The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 represents an important opportunity for scientific exchange which can benefit patients and the neurology research community. Bristol Myers Squibb looks forward to sharing 13 company-sponsored presentations at this year’s meeting. The presentations demonstrate our commitment to advancing pathbreaking science for individuals living with relapsing forms of multiple sclerosis and other serious immune-mediated diseases.

Taking back control: MS patients preserve body and mind >

Learn more about how MS patients engage in activities to help preserve their body and mind.

Family, science, community: Matt Labrecque’s experience with MS >

Hear from Matt, who works as a scientist at Bristol Myers Squibb, about his journey with MS.

MS in harmony: helping people living with MS achieve mind-body harmony through music therapy >

Bristol Myers Squibb and the American Music Therapy Association are partnering with Ben Platt to encourage people living with MS to give this unique, and fun, intervention a try.

Delivering meaningful innovations for the MS community >

Learn about how Bristol Myers Squibb is focused on delivering meaningful innovations to help, with the goal of preserving physical and cognitive function in people living with MS.

Multiple sclerosis >

Learn about the different types of MS and its potential impact on patients.

Multiple sclerosis and the brain >

Learn more about MS and how it affects the brain. 

Music therapy and multiple sclerosis >

Learn more about the relationship between MS and music therapy.